Resource impact statement
NICE has recommended etrasimod as an option for moderately to severely active ulcerative colitis in people aged 16 years and over when:
- conventional or biological treatments cannot be tolerated or
- the condition has not responded well enough, or lost response to treatment and
- the company provides it according to the commercial arrangement.
We expect the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £8,800 per 100,000 population, based on a population for England of 56.6 million people).
This is because the technology is a further treatment option and the overall cost of treatment for this patient group will be similar.
The previously published template for this patient group has been updated and replaced to include etrasimod and all other treatment options for moderately to severely active ulcerative colitis.
Organisations should complete both current and future uptake based on local practice in order to assess the financial impact.
The company has a commercial arrangement. This makes etrasimod available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discount. The other treatment options have discounts that are commercial in confidence. For enquiries about Patient Access Scheme (PAS) discounts contact the company, alternatively there may be confidential discounts at local or national levels arranged through networks.
This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
This page was last updated: